Director, Cancer Biology Program, Cancer Institute
|Associate Professor, Medicine|
Awards and Activities
|Society for Basic Urologic Research Young Investigator Award||2009|
|Ortho-McNeil Young Investigator Award||2002|
|AACR-AFLAC Scholar-in-Training Award||2002|
|Aventis Pharmaceuticals Leadership Development in Cancer Research Award||2002|
|Franklin Distinguished Doctoral Award||1997|
Examination of the role of tissue fibroblastic cells in epithelial cancer initiation and progression. Understanding stromal-epithelial interactions prostate cancer progression and mediators of metastatic progression in bone through the use of in vivo model systems. Development of biomarkers that distinguish indolent and aggressive prostate cancer.
Identified the role of stromal paracrine factors in the initiation of prostate cancer through the use of transgenic mouse models, currently targets for therapeutic trails for patients with metastatic prostate cancer. Identification of parallel TGF-ß downstream signaling pathways in epithelial and fibroblastic cells.
- Bhowmick NA: Metastatic ability: adapting to a tissue site unseen. Cancer Cell, 22(5): 563-4, 2012
- Jackson 2nd, Placzek W, Fernandez A, Ziaee S, Chu CY, Wei J, Stebbins J, Kitada S, Fritz G, Reed JC, Chung LW, Pellecchia M, Bhowmick NA: Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Neoplasia, 14(7): 656-65, 2012
- Kiskowski MA, Jackson 2nd, Banerjee J, Li X, Kang M, Iturregui JM, Franco OE, Hayward SW, Bhowmick NA: Role for stromal heterogeneity in prostate tumorigenesis. Cancer Res., 71(10): 3459-70, 2011
- Stabler S, Koyama T, Zhao Z, Martinez-Ferrer M, Allen RH, Luka Z, Loukachevitch LV, Clark PE, Wagner C, Bhowmick NA: Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS ONE, 6(8): e22486, 2011